DRKS00026238已完成不适用
Pilotstudy about the role of regulatory immune cells in autoimmunity, cancer and organ rejection after kidney transplantation - /
Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie0 个研究点目标入组 485 人开始时间: 2021年9月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 485
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Group 1: Healthy participants: healthy participants with no history of autoimmune diseases, transplantation or cancer diseases / Group 2: Type 1 Diabetes Mellitus patients: Manifested type 1 diabetes mellitus as defined by treating physicians / Group 3: Rheumatoid Arthritis patients: Manifested rheumatoid arthritis as defined by 2010 ACR/EUCLAR criteria / Group 4: Systemic Lupus erythematodes patients: Manifested systemic lupus erythematodes as defined by the 2012 SLICC crietria / Group 5: Systemic sclerosis patients: Manifested systemic slcerosis as defined by the EULAR/ACR 2013 classification criteria / Group 6: Cancer patients: Histologically confirmed colo-rectal cancer / Group 7: Kidney transplant recipients: Patients who received a first kidney transplantation
排除标准
- •Exclusion criteria for all patients involved in this study: pregnancy; acute or chronic infection / Exclusion criteria per defined study-subgroup:
- •Group 1: Healthy participants: any history of autoimmune diseases, transplantation or cancer diseases; glucocorticoid or immunosuppressive therapy within the last 3 months; manifest Type 2 diabetes mellitus / Group 2: Type 1 Diabetes Mellitus patients: glucocorticoid or immunosuppressive therapy within the last 3 months; neoplastic diseases / Group 3: Rheumatoid Arthritis patients: neoplastic diseases / Group 4: Systemic Lupus erythematodes patients: neoplastic diseases / Group 5: Systemic sclerosis patients: neoplastic diseases / Group 6: Cancer patients: ongoing chemotherapy; ongoing immunotherapy; ongoing therapy with biologicals; existence of an auto-immune disease; manifest type 2 diabetes mellitus disease / Group 7: Kidney transplant recipients: patients receiving a second, third or fourth kidney transplant; glucocorticoid or immunosuppressive therapy within the lat 3 months, AB0-incompative kidney transplantation
研究者
相似试验
尚未招募
不适用
Study for the regulation mechanism of body immune function by meditatioITMCTR1900002782Beijing University of Chinese Medicine
进行中（未招募）
1 期
PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL SUPPRESSION AND UNFAVOURABLE IMMUNOLOGIC RESPONSE (DISCORDANT PATIENTS: V+I-).Infección VIH-1MedDRA version: 9Level: LLTClassification code 10008919Term: Chronic HIV infectionEUCTR2008-005473-35-ESFundació Lluita contra la SIDA44
招募中
不适用
A pilot study to investigate the immunological regulation of preeclampsiaO14Pre-eclampsiaDRKS00025864Carl von Ossietzky Universität Oldenburg/Klinikum Oldenburg; Universitätsklinik für Gynäkologie und Geburtshilfe200
已完成
不适用
Expression of immune-related signal regulatory protein on peripheral blood mononuclear cells in non-small cell lung cancer patientsblood screeningPBMCsmall cell lung cancernon-small cell lung cancerlung cancerTCTR20190508003/A60
招募中
不适用
Study on the importance of cellular immune response in malignant tumors, autoimmune diseases, immunodeficiency syndromes, after organ transplantation and during pregnancyCancer, Autoimmune Diseases, Immune Deficiency Syndromes, PregnancyDRKS00008016niversitätsklinikum Köln1,000